As mentioned, 23andme uses genotyping not sequencing so it's unclear whether there data is that valuable for target discovery. and while it's not unprecedented for pharma to spend $300M for a target id deal, it is quite rare
I think your point still stands though, your genotype is still identifying information and should be safeguarded.
https://customercare.23andme.com/hc/en-us/articles/202904600...
Their prices are low for the "consumer" (product). The $300 million GSK deal is an example of how they can make real money.
yet
There's probably already some mad biohacker out there doing this as we speak and being called a loon by everyone who knows them.
Sequencing studies really don't show this.
Sequencing finds rare variants. GWAS finds loci with common variants. We know that for many common diseases, the population-level variability due to rare variants is small. If you want to find drug targets, there is plenty of reason to use both approaches.
"Blinded to patient identity" is true, but it can be relatively easy to re-identify these individuals using this data. So this data has your identity intertwined with potentially very private information. Some people intuitively desire to be as cautious as possible with their genetic information, and there is good reason for caution. Worst case it somehow ends up on the black market. You can't change your DNA, so if it gets out, there is no turning back.